RECEPTOR.AI
Receptor.ai develops an integral AI-based approach, which combines the best features of protein- and membrane-targeting compounds to create drugs with superior properties. Our AI algorithms are trained on extensive set of public and proprietary experimental data, clinical trials data and the results of in-house numerical simulations. The company's mission is to create superior drugs, which are safe, efficient and successful in clinical trials by developing a next-generation drug discovery platform based on the synergy of AI, computational chemistry and biomimetic technologies, such as organs-on-a-chip.
RECEPTOR.AI
Industry:
Artificial Intelligence Biotechnology Health Care Machine Learning Medical Pharmaceutical
Founded:
2021-02-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.receptor.ai
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
500 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Content Delivery Network Nginx Euro Amazon Google Apps For Business Amazon S3 CDN
Similar Organizations
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
Current Employees Featured
Founder
Official Site Inspections
http://www.receptor.ai Semrush global rank: 8.07 M Semrush visits lastest month: 379
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "RECEPTOR.AI"
RECEPTOR.AI - Crunchbase Company Profile & Funding
Receptor.AI is a TechBio company developing generative AI techniques to design first-in-class therapeutics. Its multi-platform ecosystem is built to address …See details»
About Us - RECEPTOR.AI
Receptor.AI is a pioneering TechBio company transforming drug discovery through a validated, AI-powered multiplatform ecosystem.We specialize in developing advanced platforms that address the most complex and previously …See details»
RECEPTOR.AI - LinkedIn
Receptor.AI is a next-generation TechBio company revolutionizing drug discovery with a multiplatform AI-powered ecosystem. We specialize in designing small molecules, peptides, and drug conjugates ...See details»
RECEPTOR.AI 2025 Company Profile: Valuation, …
RECEPTOR.AI was founded in 2021. Where is RECEPTOR.AI headquartered? RECEPTOR.AI is headquartered in London, United Kingdom. What is the size …See details»
RECEPTOR.AI - The Org
Receptor.AI provides an AI-powered drug discovery platform for pharma, biotech and academia that covers the whole drug discovery pipeline. Industries. AI/ML, Biotechnology + 2. Headquarters. Boston, United States.See details»
RECEPTOR.AI - Leadership Team - The Org
The Leadership Team at RECEPTOR.AI is responsible for setting the strategic vision and driving innovation within the company. Comprising key founders and executives with expertise in …See details»
RECEPTOR.AI - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Nov 13, 2024: Funding Round …See details»
Receptor.AI - Products, Competitors, Financials, Employees ...
Receptor.AI has curated a vast library consisting of approximately 4.3 billion in silico-generated small molecule compounds for screening, including 25 known to bind FADS1 (known as …See details»
Alan Nafiiev - RECEPTOR.AI - LinkedIn
I'm the founder and CEO of Receptor.ai, where we're building next-generation AI… · Experience: RECEPTOR.AI · Education: National Technical University …See details»
RECEPTOR.AI - Company info. interviews, news
Nov 14, 2022 This AI Startup Joins Forces With NVIDIA's BioNeMo to Boost Drug Discovery Feb. 19, 2024 Receptor.AI, a London-based drug discovery company and NVIDIA Inception member, has successfully integrated NVIDIA …See details»
Receptor.AI aims to democratize drug discovery, making its AI …
Sep 2, 2022 ArtiDock from Receptor.AI: next-generation AI docking that beats DiffDock and AlphaFold-latest Dec 1, 2023 Targeting cryptic pockets with Receptor.AI drug discovery platformSee details»
RECEPTOR.AI | AI-Driven Drug Discovery
40+ proprietary AI models are applied to design novel drugs for precision medicine using proprietary multi-level selectivity assessment Experimental Feedback via Active Learning …See details»
Public launch of the Receptor.AI SaaS platform for drug discovery
Jul 11, 2022 Receptor.AI is delighted to announce the public launch of the SaaS platform for AI-accelerated virtual screening of multi-billion chemical spaces within an hour.. Our platform has …See details»
Receptor.AI “democratizes” automated AI solutions for drug …
Jul 18, 2022 Receptor.AI is a British company founded in early 2021 with an R&D department based in Kyiv, Ukraine. Despite the ongoing devastating Russian invasion of Ukraine, the R&D …See details»
RECEPTOR.AI - Org chart - The Org
Explore RECEPTOR.AI's organizational chart. Discover current team members including executives, board members, and advisors.See details»
Receptor.AI - Medium
Mar 14, 2023 Receptor.AI provides an AI-powered drug discovery platform for pharma, biotech and academia that covers the whole drug discovery pipeline in a scalable manner.See details»
Receptor.AI Opens Headquarters in Boston, Strengthening U.S.
Receptor.AI is pleased to announce the expansion of its U.S. presence by establishing a new headquarters in Boston, Massachusetts, while maintaining its existing headquarters in London, …See details»
Nucleic acid spheres for treating capillarisation of liver sinusoidal ...
2 days ago Due to the predominant presence of miRNA in extracellular vesicles, an artificial intelligence (AI) model was developed to discern the active miRNA by collaboratively …See details»
Bridging the AI skills gap in your organization
2 days ago A growth mindset would reframe it: “AI is changing how we work—and I can learn new skills to grow alongside it.” Cultivating a growth mindset within your organization builds …See details»
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain …
1 day ago Voyager Therapeutics (VYGR) has published groundbreaking research in Molecular Therapy demonstrating how alkaline phosphatase (ALPL) can transport novel AAV capsids …See details»